(Q37892556)

24 August 2017

1 reference

title

Vancomycin dosing and monitoring 2 years after the guidelines (English)

1 reference

24 August 2017

1 reference

Ben M Lomaestro

1

1 reference

24 August 2017

publication date

1 June 2011

1 reference

Expert Review of Anti-infective Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

9

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

657-667

1 reference

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

24 August 2017

cites work

1 reference

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children

21 January 2018

1 reference

Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits?

21 January 2018

1 reference

Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period

21 January 2018

1 reference

Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics

21 January 2018

1 reference

Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides

21 January 2018

1 reference

Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used

21 January 2018

1 reference

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

21 January 2018

1 reference

Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin

21 January 2018

1 reference

Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia

21 January 2018

1 reference

Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin

21 January 2018

1 reference

Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection

21 January 2018

1 reference

Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia?

21 January 2018

1 reference

Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy

21 January 2018

1 reference

Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial density

21 January 2018

1 reference

Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications

21 January 2018

1 reference

Hospital policies and practices on prevention and treatment of infections caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid

21 January 2018

1 reference

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

21 January 2018

1 reference

Use of vancomycin in pediatrics

21 January 2018

1 reference

Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia

21 January 2018

1 reference

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

21 January 2018

1 reference

Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

Dosing in obesity: a simple solution to a big problem.

21 January 2018

1 reference

An unusual case of acute kidney injury due to vancomycin lessons learnt from reliance on eGFR.

21 January 2018

1 reference

Human organ/tissue growth algorithms that include obese individuals and black/white population organ weight similarities from autopsy data

21 January 2018

1 reference

Estimating the glomerular filtration rate in obese adult patients for drug dosing.

21 January 2018

1 reference

Recent changes in vancomycin use in renal failure

21 January 2018

1 reference

21 January 2018

1 reference

Optimizing initial vancomycin dosing in burn patients

21 January 2018

1 reference

Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation

21 January 2018

1 reference

Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study

21 January 2018

1 reference

Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy

21 January 2018

1 reference

Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy

21 January 2018

1 reference

Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients

21 January 2018

1 reference

Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?

21 January 2018

1 reference

Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion

21 January 2018

1 reference

Continuous infusion of vancomycin less effective and safe than intermittent infusion, based on pharmacodynamic and pharmacokinetic principles

21 January 2018

1 reference

Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates

21 January 2018

1 reference

Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury

21 January 2018

1 reference

The first international consensus conference on continuous renal replacement therapy

21 January 2018

1 reference

Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?

21 January 2018

1 reference

Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity

21 January 2018

1 reference

Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients

21 January 2018

1 reference

Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy

21 January 2018

1 reference

Vancomycin ototoxicity: a reevaluation in an era of increasing doses

21 January 2018

1 reference

Is vancomycin ototoxicity a significant risk?

21 January 2018

1 reference

Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator

21 January 2018

1 reference

In vitro susceptibility of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to manufactured generic drugs compared with the brand vancomycin

21 January 2018

1 reference

Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERI.11.46

1 reference

24 August 2017

1 reference